Pyoderma gangrenosum
Pyoderma gangrenosum ເປັນພະຍາດຜິວໜັງອັກເສບທີ່ຫາຍາກ ເຊິ່ງມີຕຸ່ມໜອງ ຫຼືຕຸ່ມທີ່ເຈັບປວດ ກາຍເປັນບາດແຜທີ່ຈະເລີນເຕີບຂຶ້ນເລື້ອຍໆ. Pyoderma gangrenosum ບໍ່ຕິດເຊື້ອ. ການປິ່ນປົວອາດຈະປະກອບມີ corticosteroids, ciclosporin, ຫຼື monoclonal antibodies. ເຖິງແມ່ນວ່າມັນສາມາດສົ່ງຜົນກະທົບຕໍ່ຄົນໃນທຸກໄວ, ມັນສ່ວນຫຼາຍແມ່ນຜົນກະທົບຕໍ່ຄົນໃນ 40s ແລະ 50s ຂອງເຂົາເຈົ້າ.
☆ ໃນປີ 2022 Stiftung Warentest ຜົນໄດ້ຮັບຈາກເຢຍລະມັນ, ຄວາມພໍໃຈຂອງຜູ້ບໍລິໂພກກັບ ModelDerm ແມ່ນຕໍ່າກວ່າການປຶກສາຫາລືທາງດ້ານການປິ່ນປົວທາງໂທລະສັບເລັກນ້ອຍເທົ່ານັ້ນ.
ຢູ່ຂາຄົນມີບາດແຜຖະຫຼອກຕາມຕົນຕົວ.
relevance score : -100.0%
ReferencesPyoderma gangrenosum ເປັນພະຍາດຜິວອັກເສບ (inflammatory skin disease) ທີ່ສ້າງຂຶ້ນຈາກກອດຜິວ (pustules) ຫຼື ກອດຜິວຂະໜາດໃຫຍ່ (nodules) ທີ່ພັດທະນາເປັນກອດຜິວ (ulcers) ທີ່ຂະຫຍາຍຂຶ້ນແບບຕໍ່ເນື່ອງ. ມັນບໍ່ແມ່ນພະຍາດທີ່ໂດຍການຕໍ່ເຊື່ອມຕໍ່. ມັນໄດ້ຈັດປະເພດເປັນພະຍາດອັກເສບແລະເປັນສ່ວນຫນຶ່ງຂອງກຸ່ມທີ່ເອີ້ນວ່າ neutrophilic dermatoses. ສາເຫດຂອງ pyoderma gangrenosum ຊັບຊ້ອນ (complex), ກ່ຽວຂ້ອງກັບການກະທົບຂອງລະບົບພິມພັນແລະລະບົບພິມຕອບສະໜອງ (innate and adaptive immunity) ໃນຄົນທີ່ມີພັນທະພາບພັນສະໜອງ. ບໍ່ດົນມານີ້, ນັກຄົ້ນຄວ້າໄດ້ສຸມໃສ່ການຮາກຜົມເປັນຈຸດເລີ່ມຕົ້ນຂອງພະຍາດ.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum ເປັນສະພາບຜິວໜັງທີ່ຫາຍາກເຮັດໃຫ້ເກີດການຜິວຜັດ(ulcer)ທີ່ເຈັບປວດທີ່ສຸດ. ໃນຂະນທີ່ພວກເຮົາບໍ່ເຂົ້າໃຈຢ່າງຄົບຖ້ວນກ່ຽວກັບສາເຫດຂອງມັນ, ພວກເຮົາຮູ້ວ່າມັນກ່ຽວຂ້ອງກັບນູໂຕຟິລ(neutrophils)ທີ່ເພີ່ມຂຶ້ນຂອງຈຸລັງພູມຕ້ານທານບາງຢ່າງ. ການປິ່ນປົວພະຍາດແມ່ນບໍ່ງ່າຍດາຍ. ພວກເຮົາມີຢາຕ່າງໆທີ່ສະກັດກັ້ນລະບົດພູມຕ້ານທານຫຼືດັດແປງກິດຈະກໍາຂອງມັນ. ຄຽງຄູ່ກັບການເຫຼົ່ານີ້, ພວກເຮົາຍັງສຸມໃສ່ການປິ່ນປົວການຜິວຜັດ(ulcer)ແລະການຄຸ້ມຄອງອາການເຈັບປວດ. Corticosteroids ແລະ cyclosporine ມັກຈະເປັນທາງເລືອກທໍາອິດສໍາລັບການປິ່ນປົວ, ແຕ່ບໍ່ດົນມານີ້, ມີການຄົ້ນຄວ້າເພີ່ມເຕີມກ່ຽວກັບການນໍາໃຊ້ການປິ່ນປົວດ້ວຍທາງຊີວະວຈະພາບ(biologics)ເຊັ່ນ TNF-α inhibitors. ຊີວະວຈະພາບ(biologics) ແມ່ນເປັນທີ່ນິຍົມຫຼາຍຂຶ້ນ, ໂດຍສະເພາະໃນຄົນເຈັບທີ່ມີສະພາບອັກເສບອື່ນໆ, ແລະພວກມັນຖືກນໍາໃຊ່ໃນຂະບວນການຂອງພະຍາດກ່ອນຫນ້ານີ້.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
